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Background/Aims: The protease inhibitors, nafamo-
stat and gabexate, have been used to prevent pan-
creatitis related to endoscopic retrograde chol-
angiopancreatography (ERCP). In vitro, nafamostat in-
hibits the pancreatic protease activities 10-100 times 
more potently than gabexate. We evaluated the effi-
cacy of nafamostat for prophylaxis against post-ERCP 
pancreatitis in comparison with gabexate. Methods: 
Five hundred patients (208 patients in the nafamo-
stat-treated group and 292 in the gabexate-treated 
group) were analyzed retrospectively after selective 
exclusion. The incidences of pancreatitis and hyper-
amylasemia after the ERCP were compared between 
the nafamostat and gabexate groups. Results: The 
incidences of acute pancreatitis and hyperamylasemia 
were 9.1% and 40.9%, respectively, in the nafamo-
stat-treated group, and 8.6% and 39.4% in the gabex-
ate-treated group. The frequencies of post-ERCP pan-
creatitis and hyperamylasemia did not differ sig-
nificantly between the two groups, Post-ERCP pan-
creatitis in two group did not vary according to the 
different ERCP procedures. The mean serum amylase 
level at 6 h after ERCP was significantly lower in the 
nafamostat-treated group than in the gabexate-treated 
group (p=0.020). However, the difference in serum 
amylase level did not persist at 18 h and 36 h 
post-ERCP.  Conclusions: Administration of nafamo-
stat before ERCP was not inferior to gabexate in pro-
tecting against the development of pancreatitis. (Gut 
and Liver 2009;3:205-210)
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INTRODUCTION
  Endoscopic retrograde cholangiopancreatography (ERCP) 
is an important procedure for the diagnosis and treatment 
of biliary and pancreatic conditions. Prospective studies 
show that acute pancreatitis occurs in 3-17% of cases fol-
lowing the ERCP and that the post-ERCP pancreatitis 
(PEP) is associated with substantial morbidity, and even 
with mortality.
1-3 Although PEP in most cases are mild, 
10% of cases progress to severe pancreatitis, resulting in 
prolonged hospital stays and life-threatening conseque-
nces.
3
  Several attempts have been made to minimize the oc-
currence and severity of PEP; identifying high-risk pa-
tients, developing less traumatic endoscopic interventions 
to limit pancreatic injury, and finding effective pharmaco-
logic agents to administer prophylactically before ERCP. 
The efficacy of such agents (somatostatin, octreotide, di-
clofenac, indomethacin, and gabexate mesylate) to reduce 
the risk of PEP had been studied extensively.
4-7
  Although the pathophysiologic precipitant of acute pan-
creatitis remains unclear, it has been demonstrated in an 
animal model which stimulation of exocrine pancreatic se-
cretion leads to further deterioration of acute pancrea-
titis.
8 Premature intracellular activation of proteolytic en-
zymes results in autodigestion, impaired acinar secretion, 
and local inflammatory responses.
9 
  Nafamostat (FUT-175; 6-amidino-2-naphthyl p-guanidi-
no-benzoate dimethane-sulfonate) is a low molecular 
w e i g h t  p r o t e a s e  i n h i b i t o r  t h a t  i n h i b i t s  s e r i n e  p r o t e a s e s  
(such as trypsin), kallikrein, C1r and C1s, complement 
activation, thrombin, and plasmin.
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shown to be 10-100 times more potent than gabexate in 
in vitro experiments,
11 and it was more effective than ga-
bexate in the treatment of necrotizing pancreatitis in a rat 
model.
12 Nafamostat has been used for the treatment of 
severe pancreatitis or prophylaxis against pancreatitis af-
ter endoscopic procedures, and no serious side effects 
were reported. However, nafamostat has scarcely been 
studied for the prophylaxis against post-ERCP pan-
creatitis.
    The present study was designed to evaluate retro-
spectively the efficacy of intravenous nafamostat in pre-
venting PEP and hyperamylasemia in comparison with 
gabexate. 
MATERIALS AND METHODS
1. Patients
    Between 2005 and 2007, 1,074 patients undergoing 
ERCP in the gastrointestinal endoscopy unit of Kangnam 
St. Mary’s Hospital (a tertiary referral center) were con-
secutively enrolled and analyzed retrospectively. Nafamo-
s t a t  o r  g a b e x a t e  w a s  a d m i n i s t e r e d  i n t r a v e n o u s l y  t o  5 0 0  
patients to prevent post-ERCP pancreatitis. Patients with 
naïve ampulla of Vater were included. Exclusion criteria 
were as follows: age＜18 years, previous surgery (Billroth 
II gastrectomy, Roux-en-Y anastomosis, and choledocho-
jejunostomy), previous sphincterotomy or biliary stenting, 
stenting into pancreatic duct, acute pancreatitis before 
ERCP, and combined use of octreotide or somatostatin.
  This study was approved by the Institutional Review 
Board of our hospital. Patient’s anonymity was preserved 
and the study protocol confirmed to the Declaration of 
Helsinki as revised in Edinburg in 2000.
2. Administration of nafamostat or gabexate and 
follow-up
   Six hundred mg of gabexate (Foy
Ⓡ; Dong-A Pharm, 
Seoul, Korea) or 50 mg of nafamostat (Futhan
Ⓡ; SK 
Chemical Life Science, Seoul, Korea) was dissolved in 5% 
glucose solution and administered by continuous intra-
venous infusion beginning 30 minutes before the endos-
copy session and continuing for 12 hours afterwards. 
Therapy with antibiotics, analgesics, and sedatives was 
permitted, whereas concomitant therapy with somatosta-
tin or octreotide was a basis for exclusion. Benzodiaze-
pines, anti-spasmodic agents, and non-narcotic analgesics, 
a l o n e  o r  i n  c o m b i n a t i o n ,  w e r e  a l s o  a l l o w e d .  I o x i t a l a m i c  
acid (Telebrix
Ⓡ, Guerbet, Roissy CdG Cedex, France), a 
water-soluble, monomeric, ionic contrast medium was 
used during the endoscopic maneuvers. One experienced 
senior endoscopist, with a career experience of over 1,000 
ERCPs and an annual ERCP caseload of over 300, directly 
performed or supervised all the procedures. If the cannu-
lation or a therapeutic procedure by a fellow-in-training 
was unsuccessful, the supervisor assumed the procedure. 
After endoscopy, patients were to in fasting state for at 
least 18 hours. Serum amylase was measured before en-
doscopy and 6, 18, and 36 hours afterward. The presence 
of abdominal pain attributable to the pancreas and the 
use and type of analgesic therapy at those times were 
evaluated.
3. Definition 
  The definition of pancreatitis was based on the con-
sensus criteria.
13 Post-ERCP pancreatitis was defined as 
the followings: a newly developed or increased abdominal 
pain within 24 hours after ERCP requiring analgesic 
agents, and the elevation of serum amylase level at least 
three times of normal upper limit around 18 hours after 
the procedure (the next morning). The severity was grad-
ed mild when hospitalization lasted 2 to 3 days, moderate 
when 4 to 10 days, and severe when hospitalization was 
prolonged for more than 10 days or any of the following 
occurred: hemorrhagic pancreatitis, pancreatic necrosis, 
pancreatic pseudocyst, or a need for percutaneous drain-
age or surgery. Hyperamylasemia was defined as an ele-
vation of serum amylase level in the morning after ERCP 
above the upper limit of normal if basal enzyme level was 
normal or as any further elevation in the enzyme if basal 
enzyme level exceeded the upper limit of normal. 
Visualization of the entire pancreatic duct by contrast in-
jection was regarded as pancreatic duct injection. Precut 
was performed at periampullary area and infundibulotomy 
was not performed.
4. Statistical analysis
  The chi-square test was used for comparisons of cate-
gorical data and student t-test was used for comparisons 
of continuous data. Serum amylase data after ERCP were 
subjected to student t-test at each time after ERCP and 
to analysis of variance with repeated measures (repeated 
measures ANOVA) through the follow-up duration. The 
statistical analyses were performed using SPSS, version 
14.0 (SPSS Inc., Chicago, IL, USA). p-values＜0.05 were 
considered significant.
RESULTS
  Five hundred patients were enrolled in the study after 
exclusion criteria were applied; 208 patients were in the 
nafamostat group and 292 patients in the gabexate group. 
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Table 1. Baseline Characteristics of the Patients
Groups
Nafamostat
(n=208)
Gabexate
(n=292)
p-value
Demographic data
  Age, years (mean±SD) 62.3±15 60.2±15 0.114
  Gender, male/female 120/88 160/132 0.520
Indication, No. of patients
  Suspected  91 (44%) 134 (46%)
   choledocholithiasis
  Obstructive jaundice  34 (16%)  49 (17%)
  P a n c r e a t i c  c y s t  o r  m a s s 3 3  ( 1 6 % )  2 4  ( 8 % )
  Dilated bile duct   22 (11%)  12 (4%)
  PSLT, biliary stricture  10 (5%)  45 (15%)
  A m p u l l a  m a s s   9  ( 4 % )   9  ( 3 % )
  O t h e r s *   9  ( 4 % )  1 9  ( 7 % )
Endoscopic procedures
  Bile duct cannulation 195 (93.8%) 281 (96.2%) 0.200
  Pancreatic duct  96 (46%) 131 (45%) 0.775
   injection
Sphincterotomy 121 (58%) 194 (66%) 0.059
Biliary stenting  51 (25%) 121 (41%) ＜0.001
  EST  42 (20%) 111 (38%) ＜0.001
  W i t h o u t  E S T   9  ( 4 % )  1 0  ( 3 % ) 0 . 6 0 3
Stone extraction  60 (29%)  86 (29%) 0.883
Performed by  16 (7%)  36 (12%) 0.094
 fellow-in-training
Precut   6 (3%)  10 (3%) 0.735
EPBD   3 (1%)   1 (0%) 0.174
Failure of bile duct    9 (4%)   9 (3%) 0.461
 cannulation
Long cannulation time  31 (15%)  50 (17%) 0.507
 ( ＞15 min)
SD, standard deviation; PSLT, post-liver transplantation; EST, 
endoscopic sphincterotomy; EPBD, endoscopic papillary bal-
loon dilatation.
*Intrahepatic lithiasis (n=10), bile leakage (n=8), chronic 
pancreatitis (n=6), acute cholangitis (n=3), and suspected 
sphincter of Oddi dysfunction (n=1).
Table 2. Incidence of Acute Pancreatitis and Hyperamylasemia 
after ERCP
Groups
Nafamostat 
(n=208)
Gabexate 
(n=292)
p-value
A c u t e  p a n c r e a t i t i s     1 9  ( 9 . 1 % )       2 5  ( 8 . 6 % ) 0 . 8 2 4
  M i l d     1 7  ( 8 . 2 % )       2 0  ( 6 . 8 % ) 0 . 5 7 7
  M o d e r a t e  t o      2  ( 1 . 0 % )        5  ( 1 . 7 % ) 0 . 4 8 1
   s e v e r e
  Biliary stenting
    Yes  5*/51 (9.8%) 12
†
/121 (9.9%) 0.982
    No 14/157 (8.9%)   13/171 (7.6%) 0.665
Hyperamylasemia     85 (40.9%)      115 (39.4%) 0.739
ERCP, endoscopic retrograde cholangiopancreatography.
*All five patients underwent endoscopic sphincterotomy; 
†
Ten 
patients underwent endoscopic sphincterotomy.
Table 3. Incidence of Pancreatitis in the Two Subgroups
Nafamostat
(n=208)
Gabexate
(n=292)
p-value
Age
≥60 11/129  9/160 0.334
＜60  8/79 16/132 0.659
Gender
Male  8/120 14/160 0.521
Female 11/88 11/132 0.313
Sphincterotomy 12/121 15/194 0.500
Pancreatic duct injection 12/96 14/131 0.672
Stenting  5/51 12/121 0.982
Stone extraction  6/60  5/86 0.346
Data are number of patients with post-endoscopic retrograde 
cholangiopancreatography pancreatitis/total number of pati-
ents in the subgroups.
t i e n t s  w e r e  f e m a l e s  ( T a b l e  1 ) .  T h e  m o s t  c o m m o n  i n -
dication for ERCP was suspected calculi in the common 
bile duct (45%) or obstructive jaundice (17%). Pancreatic 
cy st or m ass w as th e  rea so n  of E R C P  in  1 1 %  o f th e  p a-
tients, biliary stricture of post-transplantation liver in 
11%, and dilated biliary tree seen on the imaging study 
in 7%. The nafamostat and gabexate groups were similar 
in respect to patient demographics and the common dis-
tribution of indications for the procedure. In details of 
endoscopic procedures, two groups showed no difference 
except biliary stenting (p＜0.001).
  Table 2 shows the incidence of acute pancreatitis after 
ERCP. The overall incidence of acute pancreatitis was 
8.8% (9.1% in the nafamostat group and 8.6% in the ga-
bexate group). Although acute pancreatitis after ERCP oc-
curred slightly more often in the nafamostat group than 
the gabexate group, it was not statistically significant. 
The overall incidence of hyperamylasemia was 40.0% 
(40.9% in the nafamostat group and 39.4% in the gabex-
ate group), and the incidence also did not show sig-
nificant difference in two groups. Among 44 patients in 
whom developed pancreatitis, four patients in the gabex-
ate group and one patient in the nafamostat group had 
moderate pancreatitis, and one patient in each group had 
severe pancreatitis. Moderate to severe pancreatitis oc-
curred slightly more in the gabexate group, however it 
had no significance. Because the gabexate group under-
went more biliary stenting than the nafamostat group, the 
i n c i d e n c e s  o f  P E P  w e r e  c o m p a r e d  i n  t h e  s u b g r o u p s  t o  
eliminate the inclusion bias. There were no difference in 
the occurrence of PEP between the nafamostat group and 
the gabexate group according to biliary stenting. The dif-208   Gut and Liver, Vol. 3, No. 3, September 2009
Fig. 1. Serial changes in serum amylase (mean and SE values) 
before and after ERCP in the nafamostat- and gabexate-treated
groups. The mean 6-h post-ERCP serum amylase level of the 
gabexate-treated group was significantly higher than that of 
the nafamostat-treated group; however, the mean post-ERCP 
amylase level did not differ significantly between the two 
groups thereafter. The overall post-ERCP amylase levels in the 
two groups did not differ up to 36 h after ERCP (repeated- 
measures analysis of variance, p=0.296). 
ERCP, endoscopic retrograde cholangiopancreatography.
*p=0.020.
ferent types of endoscopic procedures performed and their 
associated rates of incidence of pancreatitis are shown in 
Table 3. The incidence of pancreatitis was not signifi-
cantly different in each subgroup according to endoscopic 
procedures. 
  The mean amylase levels at baseline were 68.2 U/L in 
the nafamostat group and 68.9 U/L in the gabexate group 
(Fig. 1). After ERCP, the mean amylase levels at 6 hours 
in patients in the nafamostat and the gabexate groups 
were 192.5 U/L and 252.1 U/L. The amylase level in the 
nafamostat group was significantly lower than that in the 
gabexate group (p=0.020). The mean amylase level at 18 
hours (the next morning) in the nafamostat group was al-
so lower than that in the gabexate group (254.0 U/L and 
285.7 U/L, respectively), but it was not statistically sig-
nificant. Thirty six hours after ERCP the mean amylase 
level of two groups became very close, and the difference 
in the amylase level was only 1.0 U/L. The overall com-
parison of serum amylase values showed no difference 
through 36 hours after ERCP in two groups (repeated 
measures ANOVA, p=0.296).
  Before ERCP, 42 patients had baseline serum amylase 
concentrations greater than the upper limit of normal, but 
less than 3 times the normal limit (13 patients in the na-
famostat group and 29 patients in the gabexate group). 
Twelve patients had a mild increase in the amylase level 
and five patients (11.9%) had acute pancreatitis after 
ERCP. It was not different from the incidence of PEP in 
normal baseline amylase group.
  Nine of PEP patients had radiologic evaluation of the 
pancreas 1-6 days after the ERCP. Seven patients had 
normal findings of pancreas. One patient showed peri-
pancreatic infiltration with pancreas swelling on abdomi-
nal computerized tomography four days after ERCP. The 
remaining one patient showed a radiologic finding of se-
vere pancreatitis on abdominal computerized tomography 
one day after ERCP; diffusely enlarged pancreas, large 
amount of peripancreatic fluid, and ascites at the peri-
hepatic, pericholecystic space, and right paracolic gutter. 
Follow-up abdominal computerized tomography was taken 
8 days after ERCP in this patient, and it revealed interval 
partial regression of pancreatic swelling and peripancreatic 
fluid collection. The time elapsed until amylase normal-
ized after ERCP in PEP patients was 2-17 days 
(mean±SD, 3.4±2.4 days) except for one patient. One 
patient with chronic pancreatitis had mildly elevated se-
rum amylase level until six months after ERCP. No pa-
tients died secondary to acute pancreatitis.
DISCUSSION
  In the present study, the nafamostat group showed low 
amylase level in the early phase after ERCP. However, the 
incidence of post-ERCP pancreatitis was not different be-
tween the nafamostat and gabexate group. The incidence 
of pancreatitis was also not different in subgroups accord-
ing to different endoscopic procedures. 
  Every endoscopist performing ERCP wish to avoid PEP, 
especially severe PEP. There are two approaches to avoid 
or reduce PEP. The first approach is the preventive ad-
m i n i s t r a t i o n  o f  a g e n t s  t o  d e c r e a s e  p a n c r e a t i c  p r o t e a s e  
activity. The second approach is to determine the risk fac-
tors for PEP, including patient-related and procedure-re-
lated factors. Many studies have focused on these issues. 
Prevention of PEP with gabexate has been the subject of 
several studies. Some have demonstrated that gabexate is 
effective in reducing the incidence of post-ERCP pan-
creatitis,
1,14-16 yet others did not find any benefit in ad-
ministering the drug.
17,18 In the present study, the in-
cidences of hyperamylasemia and acute pancreatitis in the 
gabexate group were 39.4% and 8.6%, respectively, which 
are similar or a little higher than other prospective 
studies.
1,14,17,18 Patient selection, indications for ERCP, 
therapeutic maneuvers performed, and different modalities 
of administering the drug are likely to explain the differ-
ent results.
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aberrantly activated proteases with subsequent inflamma-
tion and tissue destruction are thought to be crucial in 
the development of acute pancreatitis. These early events 
in the course of this disease had been found by previous 
experimental studies in which the activation of trypsin re-
sulting from the fusion of zymogen granules and lyso-
somes in acinar cells, and the premature activation of 
trypsinogen in the extracellular matrix was proven to be 
the most important events.
19,20 A s  a  p r o t e a s e  i n h i b i t o r  
and a highly diffusible molecule, nafamostat may be pro-
tective against intracellular trypsin activation. Once tryp-
sin is activated, nafamostat may also play a protective 
role because it inhibits the activation of other proteases. 
Nafamostat is a very safe medication and the adverse 
events are few like gabexate. If any, they are mild and 
self-limiting conditions such as mild nausea, vomiting, 
and diarrhea. In present study, there were no life-threat-
ening or serious adverse events which required treatment 
following the administration of nafamostat. 
  The incidence of PEP in the gabexate group was slight-
ly lower (0.5%) than in the nafamostat group, and it was 
not statistically significant. When α is 0.05, the lower 
one-sided 95% confidence interval for difference of pan-
creatitis incidence was calculated as −3% in the present 
study.
21 If the specific limit for the least relevant differ-
ence of PEP incidence is ±5%, the calculated lower con-
fidence interval (−3%) lies above the specific limit for 
the least relevant difference. It indicates that the effect of 
nafamostat is not inferior to the effect of gabexate for the 
prevention of PEP. In addition, type 2 error risk over-
looking the effect of the least relevant difference (5%) 
was estimated at 0.041 (the power was 95.9%).
21 There-
fore, our result shows that the effect of nafamostat was 
not inferior to gabexate with a sufficient power.
  Among 42 patients with slightly elevated serum amy-
lase concentrations at baseline without abdominal pain, 
12 patients (28.6%) showed a mild increase of amylase 
level after ERCP and PEP occurred in 5 patients (11.9%). 
The incidence was not significantly different from that of 
the patients with normal amylase concentration at base-
line. This finding agrees with another study involving pa-
tients with elevated serum enzyme levels at baseline.
14
  The limitation of this study is that it was not a pro-
spective study and there was no comparison with placebo 
group. Some of recent some meta-analysis showed pro-
phylactic use of gabexate is ineffective in reducing pan-
creatitis.
3,7,22 Because our results indicate that nafamostat 
was not inferior to gabexate in preventing PEP, the effi-
cacy of nafamostat for prophylaxis pancreatitis may not 
be clearly confirmed without comparison with placebo. 
Although the patients with no preventive treatment ex-
isted in our study population, the number of patients was 
too small to be compared with other groups. One study 
which was performed in the same country as our study 
and had similar including population showed that the in-
cidence of PEP in the placebo group was 9.9% being a lit-
tle higher than our result (8.8%).
23 However, it could not 
be said that this difference had significance. Therefore, 
the further study would be needed in Asian countries in 
which gabexate and nafamostat was frequently used. 
    In conclusion, administration of nafamostat before 
ERCP was not inferior to gabexate in protecting against 
the development of pancreatitis. Further prospective rand-
omized study would be performed to compare with place-
bo in the future.
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